The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nervi, S.
Right arrow Articles by Naquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nervi, S.
Right arrow Articles by Naquet, P.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes Type 1
The Journal of Immunology, 2000, 165: 5874-5883.
Copyright © 2000 by The American Association of Immunologists

Specific Deficiency of p56lck Expression in T Lymphocytes from Type 1 Diabetic Patients1

Solange Nervi*, Catherine Atlan-Gepner*, Brigitte Kahn-Perles{dagger}, Patrick Lecine{dagger}, Bernard Vialettes*, Jean Imbert{dagger} and Philippe Naquet2,{ddagger}

* UPRES-EA2193, Institut Fédiratif de Recherche 35, Physiopathologie Métabolique et Nutritionnelle, Université de la Méditerranée, Centre Hospitalier Universitaire Timone, Marseille, France; and {dagger} Institut National de la Santé et de la Recherche Médicale Unité 119, Institut Fédiratif de Recherche 57, and {ddagger} Centre d’Immunologie, Institut National de la Santé et de la Recherche Médicale-Centre National de la Recherche Scientifique de Marseille-Luminy, Institut Fédiratif de Recherche 57, Institute of Immunology and Cancer, Marseille, France


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Peripheral T lymphocyte activation in response to TCR/CD3 stimulation is reduced in type 1 diabetic patients. To explore the basis of this deficiency, a comprehensive analysis of the signal transduction pathway downstream of the TCR/CD3 complex was performed for a cohort of patients (n = 38). The main result of the study shows that T cell hyporesponsiveness is positively correlated with a reduced amount of p56lck in resting T lymphocytes. Upon CD3-mediated activation, this defect leads to a hypophosphorylation of the CD3{zeta}-chain and few other polypeptides without affecting the recruitment of ZAP70. Other downstream effectors of the TCR/CD3 transduction machinery, such as phosphatidylinositol 3-kinase p85{alpha}, p59fyn, linker for activation of T cells (LAT), and phospholipase C-{gamma}1, are not affected. In some patients, the severity of this phenotypic deficit could be linked to low levels of p56lck mRNA and resulted in the failure to efficiently induce the expression of the CD69 early activation marker. We propose that a primary deficiency in human type 1 diabetes is a defect in TCR/CD3-mediated T cell activation due to the abnormal expression of the p56lck tyrosine kinase.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Type 1 diabetes (1) is a T cell-mediated autoimmune disease leading to the destruction of pancreatic islet {beta} cells. The severity of the disease is influenced by environmental and genetic factors, which may either delay or accelerate the onset of the overt disease (2, 3). Among the putative loci of predisposition identified, several genes regulating immune responses are candidates (4). The major susceptibility locus is linked to the MHC region, the expression of specific MHC alleles being necessary but not sufficient for the appearance of diabetes in rodents and humans (5). The involvement of other predisposition genes is suspected to explain the numerous immunological abnormalities shared in different models of type 1 diabetes. In humans, one of these immune phenotypes is characterized by low proliferation and poor cytokine production by T lymphocyte in response to TCR/CD3-mediated agonists in vitro (6, 7). The reduced T cell activation can be partially compensated by additional costimulatory signals, such as combinations of CD2/CD28 mAbs or exogenous cytokines. These results are in favor of a constitutive defect in the TCR/CD3 transduction pathway. A comparable phenotype has been described in the nonobese diabetic (NOD)3 mouse model for which thymocyte proliferation was used as a readout of T lymphocyte hyporesponse (8). In this model, a normal in vitro proliferative response can be recovered by the addition of exogenous IL-4, and systemic IL-4 injection in disease-prone female NOD mice can prevent the development of diabetes (9, 10). The development of diabetes can also be abrogated by the injection of proinflammatory cytokines such as TNF (11, 12, 13) or by intercurrent infections (14). All these observations support the notion that a deficient rather than an exaggerated T cell response might predispose to the development of type 1 diabetes (15).

Several groups undertook a more refined exploration of the signal transduction pathway downstream of the TCR/CD3 complex in mice and humans. As for several receptors, early events in T cell activation require the recruitment of protein tyrosine kinases (PTK). In T lymphocytes, the coengagement of the TCR/CD3 complex with the CD4 or CD8 coreceptors brings the p56lck tyrosine kinase in the vicinity of the CD3 chains (16, 17). This kinase phosphorylates the CD3{zeta} immunotyrosine activation motifs allowing the docking of the Syk-family tyrosine kinase ZAP70, which in turn phosphorylates neighboring linker proteins such as linker for activation of T cells (LAT). Adaptor proteins accumulate on this scaffold and recruit several key effector enzymes such as phospholipase C-{gamma}1 (PLC-{gamma}1) or the p21ras GTPase. Further downstream events will trigger a Ca2+ influx and activation of PKC and mitogen-activated protein kinases (MAPK). Whereas full T cell activation requires the simultaneous activation of all these pathways, several reports described that a partial activation signal can trigger a state of T cell unresponsiveness or skew the engagement of effector functions (18, 19). Although different signal transduction mechanisms are involved, incomplete activation signals can be due to a less efficient recognition of MHC-bound peptides, to a lack of engagement of costimulatory molecules such as CD28, or to the sequestration of the coreceptor as described for the CD4 molecule by the gp120 molecule in HIV-infected patients (20). In the NOD mouse, the defective T cell activation is associated with an impairment of the p21ras/MAPK pathway due to the reduced recruitment of the Grb2-sos complex to the cell membrane (21). Although the mechanisms might not be directly related, the same authors described the enhanced engagement of the p59fyn-Cbl pathway and a sequestration of the CD4-associated p56lck from TCR/CD3 complexes (22). All these modifications of the TCR/CD3-dependent activation cascade seem to locate a putative defect during the early stages of NOD thymocyte activation. We have recently characterized a cohort of diabetic patients in whom a similar defect in TCR/CD3-mediated activation was documented (7). In this study, a more systematic analysis of the early activation stages in peripheral T cells was performed. The main result of the study shows that the T cell hyporesponsiveness is positively correlated with a reduced amount of p56lck. In some patients, this deficit could be attributed to reduced levels of p56lck mRNA.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Patient and control groups

A group of 38 patients fulfilling the American Association of Diabetes classification criteria for type 1 diabetes (1) (age 36 ± 10 years, range 15–56 years, 19 female and 19 male) was studied. They were all insulin treated, the mean diabetes duration was 12.9 ± 6.1 years, and the mean HbA1C level was 7.5 ± 0.9%. These patients did not receive any medication susceptible to influence lymphocyte function. A group of 13 type 2 diabetic patients (age 58.9 ± 8.5 years, range 44–69 years, 10 male and 3 female, mean diabetes duration 11.7 ± 6.1 years, mean HbA1C 7.3 ± 1.6%) was also included. Seven of them were treated with insulin. A group of 24 healthy volunteers (age 34.5 ± 10 years, range 17–53 years, 18 female and 6 male) without any familial history of autoimmunity was analyzed as controls. None of the diabetic patients or control subjects suffered at the time of the enrollment from any acute or chronic infectious disease. The local Ethics Committee approved the protocol of the study, and informed consent was obtained from the participating subjects. In the text, the type 1 diabetic patients will be referred as patients.

Cells and Abs

PBMCs were obtained by Ficoll-Hypaque density centrifugation from heparinized peripheral venous blood (30 ml). Cells were rested overnight in RPMI 1640 supplemented with 4 mM glutamine and 10% heat-inactivated FBS, and the nonadherent cells were collected. This T cell-enriched population contained >85% CD3+, <3% CD14+, and <4% CD19+ cells, as determined by FACScan flow cytometric analysis (Becton Dickinson, Mountain View, CA), and the percentage of CD3+ cells was comparable in patient and control populations. Furthermore, in several cases, a more complete cytometric analysis was performed using activation or differentiation T cell markers defined by mAbs to CD25, CD69, CD62L, CD45RA, CD45RO epitopes (Immunotech, Luminy, France/Becton Dickinson). Results obtained from 10–20 patients confirmed the absence of preactivated T lymphocytes at the time of the assay, and no increase of memory vs naive T cell populations over controls (data not shown). The purified 289 anti-human CD3{epsilon} mAb used for cell stimulation was obtained from Dr. A. Moretta (Cancer Institute, Genova, Italy). mAbs or polyclonal Abs to p56lck (3A5), p59fyn (15), TCR{zeta} (6B10.2), and phosphatidylinositol 3 (PI3)-kinase p85{alpha} (B-9) were purchased from Santa Cruz Biotechnology (Tebu, France). Abs to LAT, PLC-{gamma}, or phosphotyrosine residues 4G10 were purchased from Upstate Biotechnology (Euromedex, France). The anti-ZAP70 rabbit polyclonal serum n°142 was provided by Dr. F. Vély (Center d’Immunologie de Marseille-Luminy, Marseille, France). HRP-conjugated anti-mouse or anti-rabbit IgG Abs were purchased from Dako (Roskilde, Denmark).

Immunoblotting, immunoprecipitations, and quantification

Cells were preincubated with 10 µg/ml of anti-CD3 mAb for 30 min on ice, prewarmed at 37°C for 2 min, and stimulated for various times with 25 µg/ml of goat anti-mouse F(ab')2 Ab (Coulter, Palo Alto, CA). After brief centrifugation, cells were resuspended for 30 min at 4°C in lysis buffer containing 1% Nonidet P-40, 1 mM HEPES, 50 mM NaCl, 50 mM NaF, 0.1 mM Na3VO4, 10 mM iodoacetamid supplemented with a commercial cocktail of protease and phosphatase inhibitors (Boehringer Mannheim, Indianapolis, IN). In some experiments, Triton X-100 or Brij 96 replaced Nonidet P-40. Lysates were clarified by centrifugation at 13,000 x g for 15 min at 4°C, and the protein concentration of cell lysate was evaluated using the Bradford assay (Bio-Rad Laboratories, Richmond, CA). Samples (corresponding to 25 µg of proteins) were boiled for 5 min in 2x reducing sample buffer. Alternatively, equivalent numbers of cells were directly boiled in SDS buffer (2% SDS, 0.125 M Tris-HCl, pH 6.8, 20% glycerol, 1% 2-ME) to allow a complete solubilization and to avoid in vitro proteolysis. Samples were resolved on 10% SDS-PAGE and transferred on polyvinylidene difluoride membranes (Millipore, Bedford, MA). After saturation in 0.1% Tween-20, 5% BSA, TBS, the membranes were blotted using relevant primary and secondary Abs for 1 h, and bound Abs were visualized by enhanced chemiluminescence (Amersham, Arlington Heights, IL). For immunoprecipitation, 500 µg of precleared Nonidet P-40 cell lysates were incubated with 5 µl of rabbit polyclonal Ab or with 10 µg of mAb at 4° for 2–16 h, followed by addition of 100 µl of 40% slurry of protein A/G agarose (Amersham Pharmacia, Piscataway, NJ) for 1 h at 4°C. Agarose-bound immune complexes were washed three times in lysis buffer, solubilized for 5 min in reducing sample buffer, loaded on 12.5% SDS-PAGE, and processed as above. In some experiments, membranes were stripped in 100 mM 2-ME, 2% SDS, 62.5 mM Tris-HCl (pH 6.7) for 30 min at 56°C, washed extensively, reblocked, and reprobed with appropriate control mAbs. Autoradiogram quantification was performed by densitometry with a BioImage analyzer (BioImage, Ann Arbor, MI). Because the amount of the p85{alpha} subunit of PI3-kinase was comparable between all assays, it was used in each experiment as the normalization standard to evaluate the amount of p56lck, p59fyn, LAT, and PLC-{gamma}1.

In vitro proliferation assays and flow cytometry

For TCR/CD3 activation, PBMCs were seeded at 5 x 105 cells/ml on anti-CD3 (10 µg/ml) or PBS-coated wells. For proliferation analysis, cells were pulsed on day 3 with 1 µCi of [3H]thymidine (Amersham) for the last 8 h, and harvested on glass fiber filters. Incorporation of radioactivity was measured using a Matrix Cell Counter (Packard, Zurich, Switzerland). For triplicate wells, the SEM was always <10% of the mean. For analysis of CD69 expression, cells were stimulated with anti-CD3 or with PMA (20 ng/ml) plus ionomycin (1 µg/ml), harvested at 24 h, and stained with an anti-CD69 PE mAb.

Confocal microscopy

Cells (106/ml) were added at room temperature on polylysine-coated coverslips (30 min), saturated with 0.2% BSA (10 min), fixed in 3.7% paraformaldehyde in PBS (20 min), washed, incubated in 50 mM PBS/NH4Cl (10 min), and permeabilized in Triton X-100 (5 min). Nonspecific staining was blocked by incubation in PBS/5% human serum (40 min). Samples were incubated with primary Ab diluted in PBS/5% FCS (20 min), washed, and fluorescently labeled with the secondary Ab (20 min). Additionally, the nuclei were stained with 7-amino-actinomycin D (diluted 1/40 in PBS; Sigma, St. Louis, MO) for 1 h. Cells were washed and mounted onto a glass slide. Optical sections (0.45 µm) were collected using a TCS 4D Leica laser-scanning confocal microscope (Heidelberg, Germany). Microscope settings were adjusted so that black level values were obtained with a mouse IgG1 isotypic control. Data are presented as individual optical sections.

Preparation of RNA, cDNA, and RT-PCR

RNA was isolated from 5 x 106 cells using Trizol reagent (Life Technologies) and converted to cDNA using oligo(dT) primers (Promega, Madison, WI) and Moloney murine leukemia virus reverse transcriptase (Life Technologies). An aliquot of the resulting cDNA (1/25) was used as template and subjected to the PCR in a mixture containing 50 µM of each primer, 1 U of Taq DNA polymerase (Life Technologies). p56lck cDNA was amplified using three pairs of primers (Table IGo: 1F/1533R, 551/831R, and 1135F/1533R). The housekeeping gene {beta}2-microglobulin was amplified as an internal control (Table IGo). PCR amplification products were resolved in 1% agarose gel and revealed by ethidium bromide staining.


View this table:
[in this window]
[in a new window]
  		Table I. Specific PCR primers for the human lck and {beta}2-microglobulin genes

 
Statistical analysis

The unpaired Student’s t test was used to analyze the differences between control and patient groups. Linear regression and correlation coefficient (r) were determined to analyze the relationship between p56lck relative levels in detergent-soluble fractions and in whole cell extracts, as well as between p56lck relative levels in detergent-soluble fractions and PBMC proliferative response. The {chi}2 test was used to estimate the statistical significance of 2 x 2 contingency tables. Values of p < 0.05 were considered as statistically significant in all used tests.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Altered pattern of protein tyrosine phosphorylation in PBMCs from type 1 diabetic patients

Early events in TCR/CD3 stimulation result in the activation of well-defined PTKs, which leads to the recruitment of downstream effector proteins (17). To investigate the molecular basis for the lymphocyte hyporesponsiveness from type 1 diabetic patients (6, 7, 23), PBMC were activated with an anti-CD3 mAb, and the global pattern of tyrosine phosphorylation was analyzed in cell lysates. Differences were observed both in resting and activation conditions. In resting state samples, phosphoproteins in the range of 30 and/or 70 kDa were detected in some type 1 diabetic patients (for the 30-kDa band, compare lanes 1 and 5 in Fig. 1GoA, lanes 1 and 4 in Fig. 1GoB; for the 70-kDa band, compare lanes 11 and 13 in Fig. 1GoC). These phosphoproteins, not necessarily associated, were observed in 47% of the patients tested (9/19) vs 7% of control subjects (1/14) ({chi}2 = 6.18, p < 0.025). To test the link with type 1 diabetes, the basal phosphorylation pattern of type 2 diabetic patients was determined, and only one of seven individuals presented a hyperphosphorylated profile. We also tested whether insulin per se might be responsible for this result. No effect of insulin was observed in a nondiabetic volunteer who has received i.v. insulin as well as in type 2 diabetic patients treated by insulin (data not shown). Alternatively, the presence of these hyperphosphorylated polypeptides in resting samples from diabetic patients might be due to variations in the relative percentage of resting/activated/memory T lymphocytes. A cytofluorometric analysis of most individuals performed at the time of the biochemical assay showed no significant difference between the percentage of activated (CD25+ or CD69+), or resting vs memory (CD62L+/CD45RA+/CD45RO+) lymphocytes from diabetic and control individuals. However, we could not formally exclude that some of these hyperphosphorylated bands might be due to contaminating non-T cells in the assay.



View larger version (78K):
[in this window]
[in a new window]
  		FIGURE 1. Abnormal tyrosine phosphorylation profiles in unstimulated or TCR/CD3-stimulated PBMC from type 1 diabetic patients. Five representative experiments are shown in A, B, and C. Cells were treated with anti-CD3 (10 µg/ml) plus goat anti-mouse IgG (20 µg/ml) for the indicated times above autoradiograms. A total of 25 µg of Nonidet P-40 cell lysates was resolved by 10% SDS-PAGE, blotted, and probed with anti-phosphotyrosine mAb (4G10). Membranes were reprobed with anti-Grb2 mAb to control homogeneous protein loading (data not shown). C, control subject; P, patient; the same identification numbers of patient and control individuals are used in all figures. Numbers on the left side of panels refer to the size (kDa) of the molecular mass markers. Closed and open triangles on the right side of the panels indicate, respectively, the hyper- and hypophosphorylated polypeptides described in Results.

 
After T cell activation, most control subjects showed enhanced protein phosphorylation (Fig. 1Go) in the range of 130, 95, 55–65, 36–40, and 20 kDa corresponding to previously described downstream effector proteins (24, 25). Similar modifications were also found in samples from patients precluding delineation of a global defect following TCR/CD3 ligation correlated with the T lymphocyte hyporesponsiveness. However, a survey involving 19 patients evidenced interindividual variations. Taken globally, a 15- to 20-kDa polypeptide corresponding to CD3{zeta} was less efficiently or less durably phosphorylated in 59% of the patients tested (10/17) vs 9% of control subjects (1/11) ({chi}2 = 6.93, p < 0.01). Examples are shown in Fig. 1Go for patients 2 (Fig. 1GoA, lanes 6–8), 3 (Fig. 1GoB, lanes 5 and 6), 4 (Fig. 1GoB, lanes 8 and 9), and 20 (Fig. 1GoC, lanes 13 and 14). In addition, three bands (33, 36, and 40–42 kDa) were less phosphorylated in 70% of the patients tested (12/17) vs none of control subjects (0/11) ({chi}2 = 13.69, p < 0.0005). Examples are documented concerning hypophosphorylation (patient 18, Fig. 1GoC, lane 6; 22, Fig. 1GoC, lane 10; 20, Fig. 1GoC, lane 14), or transient phosphorylation (patient 3, Fig. 1GoB, lanes 5 and 6; 4, Fig. 1GoB, lanes 8 and 9). Because these polypeptides might correspond to CD3{zeta}, LAT, and MAPK, which are early targets of TCR/CD3-associated PTKs, this suggested a possible defect in PTK function and prompted us to analyze the CD3{zeta}-associated ZAP70 molecule.

Differential recruitment of phosphotyrosine proteins upon stimulation via TCR/CD3 in patients

Upon TCR/CD3 activation, the CD3{zeta}-chain is tyrosine phosphorylated on immunotyrosine activation motifs by the coreceptor-associated p56lck kinase (26) and recruits the cytosolic ZAP70 kinase (27, 28, 29), which then phosphorylates downstream targets such as the adaptor protein LAT (30). The total level of immunoprecipitable ZAP70 as well as the amount of its phosphorylated, activated form was comparable between control subjects, type 1 and type 2 diabetic patients (Fig. 2GoA). In contrast, the amount of phosphorylated CD3{zeta}-chain coprecipitated with ZAP70 appeared lower in most of the tested type 1 diabetic patients (Fig. 2GoA, p < 0.05). To investigate the contribution of the TCR/CD3{zeta}-chain to this phenotype, we determined the amount of unphosphorylated and phosphorylated form of CD3{zeta}-chain under resting or activated conditions. We found no reduction in the total amount of TCR/CD3{zeta}-chain immunoprecipitated by an anti-CD3{zeta} mAb, although it was hypophosphorylated after activation in patients (Fig. 2GoB).



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 2. Differential recruitment of phosphotyrosine proteins in TCR/CD3-stimulated PBMC from type 1 diabetic patients. Unstimulated and anti-CD3-stimulated PBMC Nonidet P-40 extracts were immunoprecipitated with an anti-ZAP70 polyclonal serum (A) and an anti-CD3{zeta} mAb (B), resolved by 10% SDS-PAGE, and blotted with anti-phosphotyrosine mAb (top left panels). After stripping, membranes were revealed with the same anti-ZAP serum or anti-CD3{zeta} mAb to check for homogenous protein loading (bottom left panels). CD, type 2 diabetic patient. Quantification by densitometry of these results is shown in right panels. Histogram bars represent the means of the results obtained with 20 control subjects and 25 patients (A, right panel) or with 5 control subjects and 5 patients (B, right panel). {square}, Control subjects; , type 1 diabetes patients. Error bars correspond to SEM.

 
In most control (9/13) or type 2 diabetic (6/7) individuals, another phosphorylated polypeptide with an apparent molecular mass of 55–57 kDa was efficiently coimmunoprecipitated with ZAP70. In contrast, the amount of this phosphoprotein was significantly reduced in 16 of 25 patients (Fig. 2GoA, {chi}2 = 6.79, p < 0.01). These observations incited us to explore p56lck.

Specific reduction of p56lck protein level in resting T cells from patients

In resting lymphocytes, the p56lck molecule is predominantly localized at the cell membrane in interaction with the CD4 and CD8 coreceptors (31). Upon recognition of MHC/peptide complexes, the clustering of the TCR/CD3 and coreceptors in microdomains allows the p56lck-mediated phosphorylation of the CD3{zeta}-chain (32). Thus, the level of several transducing molecules of the TCR/CD3-associated activation pathway in unstimulated Nonidet P-40 cell lysates was investigated. These effectors included the p56lck and p59fyn src kinases, the LAT adaptor protein, and more downstream effector molecules such as the PLC-{gamma}1 and PI3-kinase p85{alpha} molecules. As shown in Fig. 3GoA, the amount of p56lck protein was specifically decreased among the tested molecules. This result was confirmed by a direct immunoprecipitation of the p56lck molecule (Fig. 3GoB). Quantification of the results obtained with a group of 10 patients and 9 control subjects showed a significant 2-fold reduction (p < 0.05) for the p56lck molecule (Fig. 3GoC). The detergent-soluble p56lck levels were then evaluated in a larger cohort of 38 patients and 24 control subjects. All patients showed a reduced level of p56lck (mean decrease 46.4 ± 26.2%), but ranged from less than 20% to subnormal levels (Fig. 3GoD). To evaluate the reproducibility of these results, five patients and three control subjects were tested at least twice at 1- to 4-mo time intervals and results were equivalent (data not shown).



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 3. Reduced p56lck expression in PBMC extracts from type 1 diabetic patients. A, Immunoblot analyses of signaling molecule expression in Nonidet P-40 extracts from unstimulated PBMC (25 µg) with specific Abs, as indicated on the left side of the panel. B, Unstimulated PBMC Nonidet P-40 extracts were immunoprecipitated and blotted with an anti-p56lck mAb. C, Quantification by densitometry: the relative densitometric values were normalized using the p85{alpha} subunit as an internal control for protein loading (10 patients and 9 control subjects). D, p56lck relative levels in a cohort of 38 patients. The horizontal bar represents the p56lck normalized content from control individuals defined as 100%. Each closed circle represents the ratio of the p56lck normalized level of the patient relative to the p56lck level of the control individuals randomly included in each experiment. E, p56lck normalized levels in whole cell extracts plotted as a function of p56lck normalized levels in Nonidet P-40 lysates (nine patients, •; three control subjects, {triangleup}). The line corresponds to the linear regression (r = 0.855, p < 0.01, n = 12).

 
An altered protein conformation might explain a less efficient immunoreactivity of the anti-p56lck used in our study. This possibility was excluded by testing two Abs to distinct p56lck epitopes, one within the SH3 domain and the other in the carboxyl-terminal domain (data not shown). The decreased p56lck detection in Nonidet P-40 lysates could be also due to an incomplete solubilization of the membrane. Similar results were obtained using other detergents, including those dissociating microdomains (data not shown). Alternatively, these mild conditions of extraction might enhance in vitro proteolysis of p56lck. To test this possibility, fresh PBMCs from nine patients and three control subjects were directly lysed and boiled in SDS buffer to obtain a complete solubilization of cellular p56lck, and the p56lck/PI3-kinase p85{alpha} ratios obtained under both experimental conditions were compared (Fig. 3GoE). A strong positive correlation was found between the two normalized values. Thus, the amount of detergent-extractable membrane-associated p56lck is representative of the available kinase in T cells.

The reduced p56lck level correlates with a lower proliferative response of PBMC from patients

The recruitment of p56lck is essential for optimal T lymphocyte activation (33, 34). As previously reported (7), the group of patients used in the present study showed a classical reduction of T cell responsiveness (Fig. 4GoA). This hyporesponsiveness was positively correlated with the p56lck relative levels (Fig. 4GoB).



View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 4. Correlation of the deficient proliferative responses and reduced p56lck levels in PBMC from type 1 diabetic patients. A, TCR/CD3-mediated proliferative response in PBMC from 17 control subjects and 23 patients. Data are expressed as average cpm of stimulated triplicate minus the cpm of an unstimulated triplicate. B, TCR/CD3-mediated proliferative responses plotted as a function of p56lck relative levels of PBMC. The line represents the linear regression (r = 0.73, p < 0.01, n = 23).

 
We then analyzed the induction of CD69 cell surface expression, an early marker of T cell activation (35). As illustrated in Fig. 5GoA, CD69 expression is undetectable on resting T lymphocytes and can be induced by the potent mitogenic combination PMA plus ionomycin in all individuals. However, the induction of CD69 expression in response to TCR/CD3 ligation was markedly reduced in a subset of patients (4/17) displaying weak p56lck levels and proliferative responses. Fig. 5GoB illustrates the dramatically reduced CD69 expression on T cells from one representative patient, as already reported (6, 36). This result suggests a specific deficiency of the TCR/CD3-transducing module rather than a global defect in T cell activation. Furthermore, it allows the definition of at least two subsets of patients distinguishable by their relative level of T cell deficiency, as evidenced in Fig. 5GoA.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 5. A subset of patients exhibits a strongly reduced early T cell response specific to TCR/CD3 stimulation. A, CD69 expression in unstimulated, PMA + ionomycin- and anti-CD3-stimulated PBMC from patients (•, n = 17) and control subjects ({triangleup}, n = 8). B, Representative FACS analysis of CD69 expression in PBMC from control subject 9 and patient 13.

 
Altogether our observations support the hypothesis that a major cause of T cell hyporesponsiveness in type 1 diabetic patients is a reduced availability of membrane-bound, TCR/CD3-associated p56lck.

Normal cellular localization of p56lck in T cells from patients

The failure to recruit p56lck in the vicinity of the TCR/CD3 complex could be due to an abnormal subcellular localization of the PTK. This possibility was tested by confocal analysis of its distribution (Fig. 6Go). In these assays, the inhibitor I{kappa}B{alpha} was used as control of cytoplasmic distribution (37). In both patients (n = 10) and control (n = 8) subjects, p56lck exhibited a preferential association to T cell plasma membrane (38, 39).



View larger version (84K):
[in this window]
[in a new window]
  		FIGURE 6. Confocal microscopy analysis of p56lck distribution in PBMC from one control subject and two patients. The green fluorescence (FITC) signal localizes p56lck, while the red fluorescence (7AAD) counterstains the nuclei. I{kappa}B{alpha} was used as a control of cytoplasmic staining.

 
Reduced p56lck mRNA level in T cells from some patients

To estimate the level of p56lck mRNA, semiquantitative RT-PCR experiments were performed using total RNA extracted from unstimulated PBMC and an optimized pair of primers targeted to exons 10–12 (Fig. 7GoA). No significant variation was observed with all tested control individuals (n = 13). In contrast, among 28 tested patients, 9 showed a dramatically reduced level of p56lck mRNA compared with a {beta}2-microglobulin standard (Fig. 7GoB). Results were confirmed several times for each sample, varying PCR cycle numbers (Fig. 7GoC) and using different pairs of primers (data not shown). For a limited number of randomly selected patient and control individuals, full-length cDNA were amplified by RT-PCR using a pair of 5'- and 3'-end primers (Table IGo, 1F/1533R), hence confirming the expression of p56lck mRNA with the expected size (data not shown). These results correlate with the low amount of p56lck protein detected in the detergent-extractable fraction, because eight of those nine patients displayed less than 40% of normal levels and exhibited an impaired T cell proliferation (Fig. 4GoB).



View larger version (48K):
[in this window]
[in a new window]
  		FIGURE 7. Analysis of the lck gene transcripts in type 1 diabetic patients by RT-PCR amplification. A, Schematic representation of human p56lck and localization of the specific primer pairs (Table IGo). B, Representative results from three control subjects and five patients. Arrows on the right side of the panel indicate the positions of the 399-bp p56lck-specific product overlapping exons 10–12 and the 250-bp product amplified from the housekeeping {beta}2-microglobulin gene mRNA. C, Representative results of PCR cycle number variation for one control subject and two patients. D, Detection of the lck exon 7 alternative splicing in transcripts from PBMC of control subjects (n = 2) and patients (n = 4). The 281- and 127-bp products correspond to the size of the expected amplification products including or not exon 7, as indicated on the right side of panel. Primer pairs used for PCR amplification are shown on the left side of each panel.

 
An alternatively spliced p56lck mRNA lacking exon 7 has been shown to be associated with a default in TCR/CD3 signal transduction (40). A RT-PCR analysis of p56lck transcripts encompassing exon 7 (Fig. 7GoD) evidenced the presence of two transcripts in all individuals tested. The sequence of the PCR amplification products confirmed the presence of transcripts with and without exon 7 (data not shown) (41). Densitometric analysis revealed no significant variation of the ratio of the two transcripts. Thus, our results indicate that this alternate form of p56lck mRNA cannot explain by itself the general reduced T cell proliferation in patients.

Clinical features of the cohort of tested patients

The main clinical and molecular features of the patients as a function of p56lck level are represented in Table IIGo. The patients with the lowest p56lck protein level did not differ from the others in terms of gender, age, duration of the disease, and metabolic control. This decrease was not associated with an earlier age of onset, as the proportion of diabetes occurring before and after puberty was similar in the two groups. The prevalence of autoantibodies directed to either glutamic acid decarboxylon or tyrosine phosphatase islet antigen 2 was also comparable. However, it is worth mentioning that the HLADQB1 0201/0302 genotype was essentially observed in the group with low p56lck protein.


View this table:
[in this window]
[in a new window]
  		Table II. Major characteristics of the type 1 diabetic patients relative to their low or subnormal p56lck protein levels

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, we show that a defect in p56lck expression is tightly associated with the lowered T lymphocyte proliferation observed in type 1 diabetic patients. This hyporesponsiveness, characterized by a reduced in vitro TCR/CD3-mediated T cell proliferation (6, 7, 36, 42), is correlated with an inefficient activation of PKC and/or p21ras activation pathways, low expression of the early T cell activation marker CD69, and IL-2 secretion. The defective T cell response can be compensated by the addition of the PKC-activating drug PMA, and is not observed with a combination of agonistic anti-CD2/CD28 mAbs (7). In the NOD mouse model of type 1 diabetes (8), the deficiency in CD3-induced thymocyte proliferation (43), reversible by addition of IL-4 (10), is correlated with a reduced activation of the p21ras pathway (15, 43) and to a sequestration of the CD4-associated p56lck molecule (22). All these results suggested the existence of an early defect following engagement of the TCR/CD3 in type 1 diabetes. To test this hypothesis, we compared early PTK-mediated signaling events triggered by anti-CD3 mAb in PBMC from a panel of patients, nonautoimmune diabetic and healthy subjects. The initial observation consisted of a reduced phosphorylation of a few polypeptides upon TCR/CD3 engagement. This phenotype was variable in intensity and between patients. Similarly, in a few control or diabetic patients, a basal hyperphosphorylated pattern complicated the analysis of the results. This basal phosphorylation could not be correlated to other activation markers such as CD25 or CD69 expression or a variable ratio between naive and memory lymphocytes. However, despite these variations, an analysis performed on a large subset of patients suggested that CD3-induced phosphorylated polypeptides such as CD3{zeta}, LAT, and MAPK might be less efficiently activated in most diabetic patients. In a conventional model of T cell activation, p56lck phosphorylates CD3{zeta}, which recruits ZAP70, leading to the activation of downstream effectors (17, 44, 45). According to this model, we expect that a deficiency in p56lck function should lead to a reduced phosphorylation of CD3{zeta}, and consecutively a diminished recruitment of ZAP70. In our study, we observed indeed a moderately but significantly reduced amount of phosphorylated CD3{zeta}, whereas the total amount of ZAP70 and of its phosphorylated form was comparable between control and diabetic individuals. Interestingly, the amount of the ZAP70-bound p56lck protein was lower in samples from diabetic patients. Several reports showed that p56lck acts as a downstream effector of ZAP70 (29, 46). It then activates the p21ras/MAPK pathway via its SH3 domain (47), leading to CD69 induction. Both CD69 expression (this study and 6) and the MAPK pathway (42) are affected in diabetes. Consequently, our results suggest that the predominant effect of a deficiency in p56lck function in diabetic individuals might affect late activation events rather the immediate recruitment of ZAP70. Furthermore, p56lck is also required for activation via CD2, CD28, and the IL-2R, and thus other pathways might also be affected and will require specific attention. In line with this hypothesis, a defect in IL-2 and soluble IL-2R secretion has already been reported in type 1 diabetic patients (23).

The mechanisms explaining p56lck reduction are most probably complex and heterogeneous. At the protein level among 38 tested patients, this deficit is experimentally defined by an at least 2-fold reduction in the amount of basal detergent-extractable p56lck for 66% of patients. Because p56lck is rapidly consumed after TCR/CD3 triggering (48), one can speculate that the deficit in type 1 diabetes could be consecutive to the apparent preactivated state observed in some patients. However, our survey (n = 14) excluded this hypothesis, as global hyperphosphorylation in resting state samples did not correlate with low p56lck protein level. Alternatively, in a model of T cell desensitization induced by soluble gp120 from HIV, a cytoskeletal sequestration has been documented that decreased the amount of membrane-bound p56lck (20). Our confocal analysis confirmed the membrane localization of the kinase. Indeed, in resting T cells, most of the available p56lck is concentrated in microdomains, which gather several effector molecules of the TCR/CD3-transduction machinery (32, 38). A relative resistance to the solubilization by mild detergents characterizes these microdomains. All the results obtained with Nonidet P-40 lysates were confirmed with detergents that dissociate microdomains or whole cell extracts. Furthermore, the amount of the control p59fyn tyrosine kinase as well as that of several other effector molecules involved in the T cell activation pathway were not affected.

Another explanation of a low recovery of p56lck might be linked to modifications of the cell membrane induced by the metabolic disorder of diabetes. Enrichment of membrane with exogenous polyunsaturated fatty acids displaces p56lck from microdomains (49). In type 1 diabetes, the {omega}-6 and -3 polyunsaturated fatty acids present in the plasma membrane of erythrocytes and platelets have been shown to be in normal or slightly increased proportion (50). However, a metabolic cause for the decrease of p56lck is unlikely. First, there was no correlation between p56lck amount and the HbA1c value, representative of the quality of metabolic control. Second, p56lck levels observed in lymphocytes of type 2 diabetic patients were apparently normal despite hyperglycemia. Finally, the normality of the GPI-anchored protein p59fyn or LAT confirms that modifications of microdomains are not involved in the reduction of the amount of p56lck. Thus, one can conclude that the lowered expression of p56lck is specific of type 1 diabetes and correlated with the lower proliferative response.

For 19 of the 28 patients tested for p56lck mRNA expression, we found no obvious explanation for the reduced amount of p56lck. In contrast, in eight patients, this reduced level was associated with a strong diminution in the amount of p56lck transcripts. The regulation of p56lck transcription is controlled by several independent mechanisms. The p56lck gene is transcribed from two widely separated promoters (51, 52). The type I (proximal) promoter is preferentially used in early fetal thymocytes and in nonlymphoid neoplasms, while the type II (distal) promoter is almost exclusively used in mature thymocytes and in normal mature T cells. In addition, an alternative splicing produces two type II (IIA and IIB) transcripts (53). The type IIA transcript is the most abundant p56lck isoform in mature T cells, and the minor type IIB mRNA lacks exon 1' encoding for the N-terminal CD4 and CD8 interaction domain (54). Preliminary RT-PCR experiments designed to specifically amplify 5' untranslated regions showed the expected preferential usage of sequences derived from the distal promoter region in the tested control and type 1 diabetic individuals (data not shown). These results tend to exclude an obvious deficiency in promoter or exon usage.

Taken in the context of diabetes, the reduction of p56lck level could not be related to any obvious clinical feature, but our cohort of patients is too small to allow any formal conclusion (Table IIGo). Our results suggest that for a given patient, the pattern of p56lck expression is time independent because patients studied several months after the initial evaluation presented the same response. The only putative correlation was found with the HLA haplotype of patients. From the available information, 7 of 19 patients with low p56lck vs 1 of 9 patients with subnormal p56lck level carried the HLA DQ{beta}1 0201/0302 genotype that is highly associated with the appearance of diabetes (55). These preliminary results would suggest that the development of the autoimmune repertoire in the context of distinct self MHC molecules could be strongly dependent upon the amount of available p56lck in thymocytes. Because the amount of p56lck plays a significant role in the establishment of a functional T cell repertoire (34, 56), these results might suggest that the deficiency observed in peripheral T cells might also be detectable in early thymic development.

Alteration of p56lck has also been found in other pathological situations, such as leprosy (57), cancer (58), rheumatoid arthritis (59), and lupus erythematosus (60). In cancer, this reduction was found to be secondary to the development of the tumors, partially reversible in vitro upon normal mitogenic stimulation and correlated with the clinical outcome (61). Nevertheless, in these pathologies, a more global reduction of molecules involved in signal transduction was observed, including the CD3{zeta} and ZAP70 molecules. This contrasts with the specific reduction observed in type 1 diabetes, and we favor the possibility that the deficiency in p56lck is a primary event. Interestingly, we have observed this phenotype in a patient before the onset of clinical type 1 diabetes. A systematic study among diabetes families and on larger cohorts might help to resolve these issues.

The functional consequences of this reduction in the amount of p56lck are of potential interest. One possibility would be that the lowered p56lck expression is preexisting before diabetes onset and is detectable among thymocytes. Several experimental arguments show that, depending upon the stage of maturation of the T lymphocyte studied, src kinases are differentially engaged in the T cell activation cascade. During intrathymic maturation, the preferential association of p56lck with the TCR/CD3 is required for the appropriate adjustment of threshold responses to autoantigens (56). Another possible consequence of this deficit would be a skewing of T cell responses in the periphery. Indeed, differentiation toward the Th2 lineage requires high levels of recruited p56lck kinase, and the introduction of a dominant-negative p56lck transgene under the control of the distal promoter to target its expression toward mature T lymphocytes inhibits Th2 cell development (62, 63). It has been proposed that the progression toward diabetes in the NOD mouse model might be associated with a relative reduction of the Th2/Th1 cell ratio (5, 56, 64, 65). Thus, the lowered p56lck expression could be the consequence of the Th1 bias in periphery, or more importantly a direct cause of the impaired Th2 lymphocyte differentiation. More refined experiments are required to formally prove this putative link but, for the first time, the deficient expression in the amount of a src kinase correlated with an impairment in T cell activation can be directly associated to the development of a type 1 diabetes in human.


   Acknowledgments
 
We thank Dr. A. Moretta for providing the 289 hybridoma cell clone; Dr. F. Vély for the anti-ZAP70 serum; C. Lipcey, R. Galindo, D. Isnardon, and Dr. C. Picard for helpful technical assistance and suggestions; Dr. J. Nunes for helpful discussions; and Drs. A.-M. Schmitt-Verhulst, C. Mawas, D. Olive, and B. Malissen for critical advice on the manuscript.


   Footnotes
 
1 This work was supported by the Institut National de la Santé et de la Recherche Médicale, and by research grants from the Ministère de la Santé et de le Solidarité (Programme Hospitalier de Recherche Clinique) and from ALFEDIAM-Novo Nordisk. The three laboratories have equally contributed to this work. Back

2 Address correspondence and reprint requests to Dr. Philippe Naquet, Centre d’Immunologie, Institut National de la Santé et de la Recherche Médicale-Centre National de la Recherche Scientifique de Marseille Luminy, Case 906, Marseille, Cedex 9, 13288 France. Back

3 Abbreviations used in this paper: NOD, nonobese diabetic; LAT, linker for activation of T cells; MAPK, mitogen-activated protein kinase; PI3, phosphatidylinositol 3; PLC, phospholipase C; PTK, protein tyrosine kinase. Back

Received for publication March 29, 2000. Accepted for publication August 17, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Alberti, K. G., P. Z. Zimmet. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Met. 15:539.
  2. Bach, J. F., L. Chatenoud, A. Herbelin, J. M. Gombert, C. Carnaud. 1997. Autoimmune diabetes: how many steps for one disease?. Res. Immunol. 148:332.[Medline]
  3. Gonzalez, A., J. D. Katz, M. G. Mattei, H. Kikutani, C. Benoist, D. Mathis. 1997. Genetic control of diabetes progression. Immunity 7:873.[Medline]
  4. Wicker, L. S., J. A. Todd, L. B. Peterson. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 13:179.[Medline]
  5. Delovitch, T. L., B. Singh. 1997. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727.[Medline]
  6. De Maria, R., M. Todaro, G. Stassi, F. Di Blasi, M. Giordano, A. Galluzzo, C. Giordano. 1994. Defective T cell receptor/CD3 complex signaling in human type 1 diabetes. Eur. J. Immunol. 24:999.[Medline]
  7. Nervi, S., C. Atlan-Gepner, C. Fossat, B. Vialettes. 1999. Constitutive impaired TCR/CD3-mediated activation of T cells in IDDM patients co-exist with normal co-stimulation pathways. J. Autoimmun. 13:247.[Medline]
  8. Zipris, D., A. H. Lazarus, A. R. Crow, M. Hadzija, T. L. Delovitch. 1991. Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice. J. Immunol. 146:3763.[Abstract]
  9. Cameron, M. J., G. A. Arreaza, P. Zucker, S. W. Chensue, R. M. Strieter, B. K. Chakrabarti, T. L. Delovitch. 1997. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159:4686.[Abstract]
  10. Rapoport, M. J., A. Jaramillo, D. Zipris, A. H. Lazarus, D. V. Serreze, E. H. Leiter, P. Cyopick, J. S. Danska, T. L. Delovitch. 1993. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med. 178:87.[Abstract/Free Full Text]
  11. Green, E. A., R. A. Flavell. 1999. Tumor necrosis factor-{alpha} and the progression of diabetes in non-obese diabetic mice. Immunol. Rev. 169:11.[Medline]
  12. Jacob, C. O., S. Aiso, S. A. Michie, H. O. McDevitt, H. Acha-Orbea. 1990. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-{alpha} and interleukin 1. Proc. Natl. Acad. Sci. USA 87:968.[Abstract/Free Full Text]
  13. Satoh, J., H. Seino, T. Abo, S. Tanaka, S. Shintani, S. Ohta, K. Tamura, T. Sawai, T. Nobunaga, T. Oteki. 1989. Recombinant human tumor necrosis factor {alpha} suppresses autoimmune diabetes in nonobese diabetic mice. J. Clin. Invest. 84:1345.
  14. Hermitte, L., B. Vialettes, P. Naquet, C. Atlan, M. J. Payan, P. Vague. 1990. Paradoxical lessening of autoimmune processes in non-obese diabetic mice after infection with the diabetogenic variant of encephalomyocarditis virus. Eur. J. Immunol. 20:1297.[Medline]
  15. Salojin, K. V., J. Zhang, J. Madrenas, T. L. Delovitch. 1998. T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease. Immunol. Today 19:468.[Medline]
  16. Malissen, B., A.-M. Schmitt-Verhulst. 1993. Transmembrane signalling through the T-cell-receptor-CD3 complex. Curr. Opin. Immunol. 5:324.[Medline]
  17. Weiss, A.. 1993. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell 73:209.[Medline]
  18. Schwartz, R. H.. 1997. T cell clonal anergy. Curr. Opin. Immunol. 9:351.[Medline]
  19. Sloan-Lancaster, J.. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363:156.[Medline]
  20. Goldman, F., J. Crabtree, C. Hollenback, G. Koretzky. 1997. Sequestration of p56lck by gp120, a model for TCR desensitization. J. Immunol. 158:2017.[Abstract]
  21. Salojin, K., J. Zhang, M. Cameron, B. Gill, G. Arreaza, A. Ochi, T. L. Delovitch. 1997. Impaired plasma membrane targeting of Grb2-murine son of sevenless (mSOS) complex and differential activation of the Fyn-T cell receptor (TCR)-{zeta}-Cbl pathway mediate T cell hyporesponsiveness in autoimmune nonobese diabetic mice. J. Exp. Med. 186:887.[Abstract/Free Full Text]
  22. Zhang, J., K. Salojin, T. L. Delovitch. 1998. Sequestration of CD4-associated Lck from the TCR complex may elicit T cell hyporesponsiveness in nonobese diabetic mice. J. Immunol. 160:1148.[Abstract/Free Full Text]
  23. Giordano, C., F. Panto, C. Caruso, M. A. Modica, A. M. Zambito, N. Sapienza, M. P. Amato, A. Galluzzo. 1989. Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes 38:310.[Abstract]
  24. van Oers, N. S.. 1999. T cell receptor-mediated signs and signals governing T cell development. Semin. Immunol. 11:227.[Medline]
  25. Kersh, E. N., A. S. Shaw, P. M. Allen. 1998. Fidelity of T cell activation through multistep T cell receptor {zeta} phosphorylation. Science 281:572.[Abstract/Free Full Text]
  26. Chan, A. C., M. Iwashima, C. W. Turck, A. Weiss. 1992. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR {zeta} chain. Cell 71:649.[Medline]
  27. Duplay, P., M. Thome, F. Herve, O. Acuto. 1994. p56lck interacts via its src homology 2 domain with the ZAP-70 kinase. J. Exp. Med. 179:1163.[Abstract/Free Full Text]
  28. Labadia, M. E., R. H. Ingraham, J. Schembri-King, M. M. Morelock, S. Jakes. 1996. Binding affinities of the SH2 domains of ZAP-70, p56lck and Shc to the {zeta} chain ITAMs of the T-cell receptor determined by surface plasmon resonance. J. Leukocyte Biol. 59:740.[Abstract]
  29. Thome, M., P. Duplay, M. Guttinger, O. Acuto. 1995. Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/{zeta} complex. J. Exp. Med. 181:1997.[Abstract/Free Full Text]
  30. Lin, J., A. Weiss, T. S. Finco. 1999. Localization of LAT in glycolipid-enriched microdomains is required for T cell activation. J. Biol. Chem. 274:28861.[Abstract/Free Full Text]
  31. Turner, J. M., M. H. Brodsky, B. A. Irving, S. D. Levin, R. M. Perlmutter, D. R. Littman. 1990. Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell 60:755.[Medline]
  32. Montixi, C., C. Langlet, A. M. Bernard, J. Thimonier, C. Dubois, M. A. Wurbel, J. P. Chauvin, M. Pierres, H. T. He. 1998. Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. EMBO J. 17:5334.[Medline]
  33. Strauss, D. B., A. Weiss. 1992. Genetic evidence for the involvement of the Lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70:585.[Medline]
  34. Penninger, J. M., V. A. Wallace, K. Kishihara, T. W. Mak. 1993. The role of p56lck and p59fyn tyrosine kinases and CD45 protein tyrosine phosphatase in T-cell development and clonal selection. Immunol. Rev. 135:183.[Medline]
  35. Ziegler, S. F., F. Ramsdell, M. R. Alderson. 1994. The activation antigen CD69. Stem Cells 12:456.[Medline]
  36. Giordano, C., R. De Maria, M. Todaro, G. Stassi, A. Mattina, P. Richiusa, G. Galluzzo, F. Panto, A. Galluzzo. 1993. Study of T-cell activation in type I diabetic patients and pre-type I diabetic subjects by cytometric analysis: antigen expression defect in vitro. J. Clin. Immunol. 13:68.[Medline]
  37. Brown, K., S. Gerstberger, L. Carlson, G. Franzoso, U. Siebenlist. 1995. Control of I{kappa}B-{alpha} proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485.[Abstract/Free Full Text]
  38. Stefanova, I., V. Horejsi, I. J. Ansotegui, W. Knapp, H. Stockinger. 1991. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 254:1016.[Abstract/Free Full Text]
  39. Caron, L., N. Abraham, T. Pawson, A. Veillette. 1992. Structural requirements for enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck. Mol. Cell. Biol. 12:2720.[Abstract/Free Full Text]
  40. Goldman, F. D., Z. K. Ballas, B. C. Schutte, J. Kemp, C. Hollenback, N. Noraz, N. Taylor. 1998. Defective expression of p56lck in an infant with severe combined immunodeficiency. J. Clin. Invest. 102:421.[Medline]
  41. Rouer, E., F. Brule, R. Benarous. 1999. A single base mutation in the 5' splice site of intron 7 of the lck gene is responsible for the deletion of exon 7 in lck mRNA of the JCaM1 cell line. Oncogene 18:4262.[Medline]
  42. Rapoport, M. J., A. Mor, P. Vardi, Y. Ramot, O. Levi, T. Bistritzer. 1999. Defective activation of p21ras in peripheral blood mononuclear cells from patients with insulin dependent diabetes mellitus. Autoimmunity 29:147.[Medline]
  43. Rapoport, M. J., A. H. Lazarus, A. Jaramillo, E. Speck, T. L. Delovitch. 1993. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation. J. Exp. Med. 177:1221.[Abstract/Free Full Text]
  44. Veillette, A., J. C. Zuniga-Pflücker, J. B. Bolen, A. M. Kruisbeek. 1989. Engagement of CD4 and CD8 expressed on immature thymocytes induces activation of intracellular tyrosine phosphorylation pathways. J. Exp. Med. 170:1671.[Abstract/Free Full Text]
  45. Molina, T. J., K. Kishihara, D. P. Siderovski, W. van Ewijk, A. Narendran, E. Timms, A. Wakeham, C. J. Paige, K.-U. Hartmann, A. Veillette, D. Davidson, T. W. Mak. 1992. Profound block in thymocyte development in mice lacking p56lck. Nature 357:161.[Medline]
  46. Wong, J., D. Straus, A. C. Chan. 1998. Genetic evidence of a role for Lck in T-cell receptor function independent or downstream of ZAP-70/Syk protein tyrosine kinases. Mol. Cell. Biol. 18:2855.[Abstract/Free Full Text]
  47. Denny, M. F., H. C. Kaufman, A. C. Chan, D. B. Straus. 1999. The Lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling. J. Biol. Chem. 274:5146.[Abstract/Free Full Text]
  48. Viola, A., S. Schroeder, Y. Sakakibara, A. Lanzavecchia. 1999. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283:680.[Abstract/Free Full Text]
  49. Stulnig, T. M., M. Berger, T. Sigmund, D. Raederstorff, H. Stockinger, W. Waldhausl. 1998. Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. J. Cell Biol. 143:637.[Abstract/Free Full Text]
  50. Tilvis, R. S., T. A. Miettinen. 1985. Fatty acid compositions of serum lipids, erythrocytes, and platelets in insulin-dependent diabetic women. J. Clin. Endocrinol. Metab. 61:741.[Abstract/Free Full Text]
  51. Sartor, O., F. S. Gregory, N. S. Templeton, S. Pawar, R. M. Perlmutter, N. Rosen. 1989. Selective expression of alternative lck mRNAs in human malignant cell lines. Mol. Cell. Biol. 9:2983.[Abstract/Free Full Text]
  52. Takadera, T., S. Leung, A. Gernone, Y. Koga, Y. Takihara, N. G. Miyamoto, T. W. Mak. 1989. Structure of the two promoters of the human lck gene: differential accumulation of two classes of lck transcripts in T cells. Mol. Cell. Biol. 9:2173.[Abstract/Free Full Text]
  53. Rouer, E., R. Benarous. 1992. Alternative splicing in the human lck gene leads to the deletion of exon 1' and results in a new type II lck transcript. Oncogene 7:2535.[Medline]
  54. Huse, M., M. J. Eck, S. C. Harrison. 1998. A Zn2+ ion links the cytoplasmic tail of CD4 and the N-terminal region of Lck. J. Biol. Chem. 273:18729.[Abstract/Free Full Text]
  55. Todd, J. A.. 1995. Genetic analysis of type 1 diabetes using whole genome approaches. Proc. Natl. Acad. Sci. USA 92:8560.[Abstract/Free Full Text]
  56. Lucas, B., I. Stefanova, K. Yasumoto, N. Dautigny, R. N. Germain. 1999. Divergent changes in the sensitivity of maturing T cells to structurally related ligands underlies formation of a useful T cell repertoire. Immunity 10:367.[Medline]
  57. Zea, A. H., M. T. Ochoa, P. Ghosh, D. L. Longo, W. G. Alvord, L. Valderrama, R. Falabella, L. K. Harvey, N. Saravia, L. H. Moreno, A. C. Ochoa. 1998. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect. Immun. 66:499.[Abstract/Free Full Text]
  58. Mizoguchi, H., J. J. O’Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795.[Abstract/Free Full Text]
  59. Matsuda, M., A. K. Ulfgren, R. Lenkei, M. Petersson, A. C. Ochoa, S. Lindblad, P. Andersson, L. Klareskog, R. Kiessling. 1998. Decreased expression of signal-transducing CD3 {zeta} chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand. J. Immunol. 47:254.[Medline]
  60. Matache, C., M. Stefanescu, A. Onu, S. Tanaseanu, I. Matei, R. Frade, G. Szegli. 1999. p56lck activity and expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus. Autoimmunity 29:111.[Medline]
  61. Gratama, J. W., A. H. Zea, R. L. Bolhuis, A. C. Ochoa. 1999. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer Immunol. Immunother. 48:263.[Medline]
  62. Singh, R. A., Y. C. Zang, A. Shrivastava, J. Hong, G. T. Wang, S. Li, M. V. Tejada-Simon, M. Kozovska, V. M. Rivera, J. Z. Zhang. 1999. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. J. Immunol. 163:6393.[Abstract/Free Full Text]
  63. Yamashita, M., K. Hashimoto, M. Kimura, M. Kubo, T. Tada, T. Nakayama. 1998. Requirement for p56lck tyrosine kinase activation in Th subset differentiation. Int. Immunol. 10:577.[Abstract/Free Full Text]
  64. Atlan-Gepner, C., L. Hermitte, B. Janand-Delenne, P. Naquet, B. Vialettes. 1997. Different TH2-TH1 balance in V{beta}8 and V{beta}6 subsets of splenocytes in NOD females in the early phase of diabetogenesis. Diabetes Metab. 23:386.[Medline]
  65. Hartemann, A. H., M. F. Richard, C. Boitard. 1999. Absence of significant Th2 response in diabetes-prone non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 116:225.[Medline]



This article has been cited by other articles:


Home page
 DiabetesHome page
J. S. Hulme, B. J. Barratt, R. C.J. Twells, J. D. Cooper, C. E. Lowe, J. M.M. Howson, A. C. Lam, L. J. Smink, D. A. Savage, D. E. Undlien, et al.
Association Analysis of the Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Gene in Type 1 Diabetes
Diabetes, September 1, 2004; 53(9): 2479 - 2482.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
E C Jury and P S Kabouridis
T-lymphocyte signalling in systemic lupus erythematosus: a lipid raft perspective
Lupus, June 1, 2004; 13(6): 413 - 422.
[Abstract] [PDF]

Home page
 DiabetesHome page
S. Nervi, S. Nicodeme, C. Gartioux, C. Atlan, M. Lathrop, D. Reviron, P. Naquet, F. Matsuda, J. Imbert, and B. Vialettes
No Association Between lck Gene Polymorphisms and Protein Level in Type 1 Diabetes
Diabetes, November 1, 2002; 51(11): 3326 - 3330.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nervi, S.
Right arrow Articles by Naquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nervi, S.
Right arrow Articles by Naquet, P.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes Type 1

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS